ООО «Лабораторная Диагностика»
ООО «Лабораторная Диагностика»  
 Главная   Новости   О компании  Каталог продукции и цены   Оформить заказ   Контакты 
 
  
Каталог продукции
  Онкология  
  Общая информация
  · Онкомаркеры
  · Виды рака
  · Методы лечения
  Методы диагностики
  · Иммуногистохимия
  · ИФА
  · Мультиплексный анализ
  · · Скрининг рака простаты
  · Проточная цитометрия
  · ПЦР
  · · Определение мутаций
  · Цитогенетическая диагностика
  Гематология  
  Гемостаз  
  Иммуногематология  
  Иммуногистохимия
  Иммуноферментный анализ (ИФА)
  Иммунохимия  
  Клеточные технологии  
  Клиническая биохимия
  Коагулометрия  
  Микробиология  
  Мультиплексный анализ  
  Оборудование для биохимии и
  молекулярной биологии
  Общелабораторное оборудование
  Пищевая промышленность  
  Программное обеспечение  
  Проточная цитометрия
  ПЦР-лаборатория
  Рекомбинантные белки
  Репродуктивные технологии
  Сортировка клеток
  Спектрофотометрия  
  Стволовые клетки (Stem Cells)
  Трансплантология
  Цитогенетическая диагностика
  Экспресс-лаборатория  

 
/ Каталог / Онкология / Общая информация / Типы злокачественных опухолей / Рак предстательной железы

Подборка литературы по раку простаты

Подборка литературы, посвященной скринингу рака простаты и ассоциированным с ним биомаркерам:

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009CA Cancer J Clin. 2009;59:225-49

2. Home page of Prostate Cancer Foundation. Prostate Cancer Foundation.http://www.prostatecancerfoundation.org

3. Stanford JL, Stephenson RA, Coyle LM. et alProstate Cancer Trends 1973-1995, NIH Pub No 99-4543. Bethesda, MD: SEER Program, National Cancer Institute. 1999

4. Prostate Cancer Screening: A Decision Guide for African Americans. US Department of Health and Human Services, Centers for Disease Control and Prevention (CDC).http://www.ustoo.org/PDFs/CDC_PCa_Screen_Guide_AA.pdf

5. Atkinson AJJr, Colburn WA, DeGruttola VG, DeMets DL. et alBiomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Biomarkers Definitions Working GroupClinical Pharmacol & Therapeutics. 2001;69:89-95

6. A Framework for Biomarker and Surrogate Endpoint Use in Drug Development. Woodcock J.http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4079S2_03_Woodcock.ppt

7. Dictionary of Cancer Terms. National Cancer Institute. http://www.cancer.gov/dictionary/?searchTxt=biomarker

8. Rolan P. The contribution of clinical pharmacology surrogates and models to drug development: a critical appraisalBr J Clin Pharmacol. 1997;44:219-25

9. Ciarmiello A, Del Vecchio S, Silvestro P. et alTumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancerJ Clin Oncol. 1998;16:1677-83

10. Committee on Developing Biomarker-Based Tools for Cancer Screening Diagnosis and Treatment. Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment. Washington DC: National Academies Press. 2007

11. Lagakos SW, Hoth DF. Surrogate markers in AIDS: where are we? Where are we going?Ann Intern Med. 1992;116:599-601

12. Sawyers CL. The cancer biomarker problemNature. 2008;452:548-52

13. Ross RK, Pike MC, Coetzee GA. et alAndrogen metabolism and prostate cancer: establishing a model of genetic susceptibilityCancer Res. 1998;58:4497-504

14. Smith RA, Mettlin CJ, Eyre H. Cancer Medicine: Cancer Screening and Early Detection. In: (ed.) Kufe DW. et alCancer Medicine. Hamilton, Canada: BC Decker Inc. 2003

15. Prostate Cancer - Biology, Diagnosis, Pathology, Staging, and Natural History. Theodorescu D, Krupski T.http://www.emedicine.com

16. Bostwick DG. The pathology of early prostate cancerCA Cancer J Clin. 1989;39:376-93

17. Stamey TA, Freiha FS, McNeal JE. et alLocalized prostate cancer treatment: relationship of tumor volume to clinical significance for treatment of prostate cancerCancer. 1993;71:933-8

18. Epstein JI, Walsh PC, Carmichael M. et alPathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancerJAMA. 1994;271:368-74

19. Ohori M, Wheeler TM, Dunn JK. et alThe pathologic features and prognosis of prostate cancers detectable with current diagnostic testsJ Urol. 1994;152:1714-20

20. Montie JM, Wood DP, Pontes JE. et alAdenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancerCancer. 1989;63:381-5

21. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screeningJ Urol.1994;152:1732-6

22. Oh WK, Hurwitz M, D'Amico AV. et alNeoplasms of the Prostate. In: (ed.) Kufe DW. et alCancer Medicine. Hamilton, Canada: BC Decker Inc. 2003

23. Yano M, Imamoto T, Suzuki H. et alThe clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screeningEur Urol. 2007;51:375-80

24. Fielding LP, Genglio-Presier CM, Freedman LS. The future of prognostic factors in outcome prediction for patients with cancerCancer. 1992;70:2367-77

25. Jewett HJ. The present status of radical prostatectomy for stages A and B prostatic cancerUrol Clin North Am. 1975;2:105-24

26. American Joint Committee on Cancer. Prostrate: in AJCC Cancer Staging Manual, 6th ed. New York, NY: Springer. 2002:309-16

27. Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancerSemin Surg Oncol. 1994;10:60-72

28. American Joint Committee on Cancer. Prostate cancer. In: (ed.) Fleming ID, Cooper JS, Henson DE, Hutter RVP. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott. 1997:219-24

29. Montie JE. Staging of prostate cancer: current TNM classification and future prospects for prognostic factorsCancer.1995;75(7 Suppl):1814-8

30. Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: The Johns Hopkins experience with tumours found on transurethral resection (stages T1A and T1B) and on needle biopsyJ Urol. 1994;152:1721-9

31. Mettlin C, Lee F, Drago J. et alThe American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 menCancer. 1991;67:2949-58

32. Catalona WJ, Smith DS, Ratliff TL. et alMeasurement of prostate-specific antigen in serum as a screening test for prostate cancerN Engl J Med. 1991;324:1156-61

33. Basler JW, Thompson IM. Lest we abandon digital rectal examination as a screening test for prostate cancerJ NCI.1998;90:1761-3

34. Mahon SM. Screening for prostate cancer: informing men about their optionsClinical Journal of Oncology Nursing. 2005;9:5

35. Yedema CA, Kenemans P, Voorhorst F. et alCA 125 half-life in ovarian cancer. A multivariate survival analysisBr J Cancer. 1993;67:1361-7

36. Jacobsen SJ, Bergstralh EJ, Katusic SK. et alScreening digital rectal examination and prostate cancer mortality: a population-based case-control studyUrology. 1998;52:173-9

37. Friedman GD, Hiatt Ram, Quesenberry CP. et alCase-control study of screening for prostatic cancer by digital rectal examinationsLancet. 1991;337:1526-9

38. Richert-Boe KE, Humphrey LL, Glass AG. et alScreening digital rectal examination and prostate cancer mortality: a case-control studyJ Med Screen. 1998;5:99-103

39. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force.Ann Intern Med. 2002;137:917-29

40. Hara M, Koyanagi Y, Inoue T. et alSome physico-chemical characteristics of “-seminoprotein”, an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VIINihon Hoigaku Zasshi.1971;25:322-4

41. Li TS, Beling CG. Isolation and characterization of two specific antigens of human seminal plasmaFertil Steril.1973;24:134-44

42. Sensabaugh GF, Golden VL. Phenotype dependence in the inhibition of red cell acid phosphatase (ACP) by folatesAm J Hum Genet. 1978;30:553-60

43. Wang MC, Valenzuela LA, Murphy GP. et alPurification of a human prostate specific antigenInvest Urol. 1979;17:159-63

44. Stamey TA, Yang N, Hay AR. et alE. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostateN Engl J Med. 1987;317:909-16

45. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigenJ Urol. 1994;152:1358-68

46. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen. A decade of discovery—what we have learned and where we are goingJ Urol. 1999;162:293-306

47. Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigenBJU Int. 2008;101:5-10

48. Chu MT. Prostate-specific antigen and early detection of prostate cancerTumor Biol. 1997;18:123-34

49. Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigenUrol Clin North Am. 1997;24:275-82

50. Stenman UH, Leinonen J, Zhang WM. Standardization of PSA determinationsScand J Clin Lab Invest (Suppl). 1995;221:45-51

51. Carter HB, Pearson JD, Metter EJ. et alLongitudinal evaluation of prostate-specific antigen levels in men with and without prostate diseaseJAMA. 1992;267:2215-20

52. Moul JW, Sesterhenn IA, Connelly RR. et alProstate-specific antigen values at the time of prostate cancer diagnosis in African-American menJAMA. 1995;274:1277-81

53. Presti JCJr, Hovey R, Bhargava V. et alProspective evaluation of prostate specific antigen and prostate specific antigen density in the detection of carcinoma of the prostate: ethnic variationsJ Urol. 1997;157:907-11

54. Morgan TO, Jacobsen SJ, McCarthy WF. et alAge-specific reference ranges for prostate-specific antigen in black menN Engl J Med. 1996;335:304-10

55. Partin AW, Yoo J, Carter HB. et alThe use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancerJ Urol. 1993;150:110-4

56. Partin AW, Carter HB, Chan DW. et alProstate specific antigen in the staging of localized prostate cancer. Influence of tumor differentiation, tumor volume and benign hyperplasiaJ Urol. 1990;143:747-52

57. Stamey TA, Dietrick DD, Issa MM. Large, organ confined, impalpable transition zone prostate cancer. Association with metastatic levels of prostate specific antigenJ Urol. 1993;149:510-5

58. Catalona WJ, Smith DS, Ratliff TL. et alDetection of organ-confined prostate cancer is increased through prostate-specific antigen-based screeningJAMA. 1993;270:948-54

59. Balducci L, Pow-Sang J, Friedland J. et alProstate cancerClin Geriatr Med. 1997;13:283-306

60. SEER Cancer Statistics Review, 1975-2005. Ries LA, Melbert D, Krapcho M, et al. http://seer.cancer.gov/csr/1975_2005/

61. Hankey BF, Feuer EJ, Clegg LX. et alCancer surveillance series: Interpreting trends in prostate cancer - Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival ratesJ Natl Cancer Inst. 1999;91:1017

62. Feuer EJ, Etzioni R, Cronin KA. et alA. The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testingStat Methods Med Res. 2004;13:421

63. Polednak AP. Estimating the prevalence of cancer in the United StatesCancer. 1997;80:136-41

64. Kirby R, Kirby M, Fitzpatrick J. et alShared Care for Prostate Disease. Oxford: ISIS Medical Media. 1994

65. Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of lifeAnnual Review of Public Health. 2001;22:91-113

66. Hakama M, Auvinen A. Cancer screening. In: (ed.) Heggenhougen Kl, Quah SR. International Encyclopedia of Public Health. San Diego, CA: Academic Press. 2008:464-80

67. Andriole GL, Grubb RL III, Buys SS. et alThe PLCO Project Team. Mortality results from a randomized Ppostate-cancer screening trialNEJM. 2009;360:1310-9

68. Aus G, Ahlgren G, Bergdahl S. et alInfection after transrectal core biopsies of the prostate--risk factors and antibiotic prophylaxisBr J Urol. 1996;77:851-5

69. Rietbergen JB, Kruger AE, Kranse R. et alComplications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening programUrology.1997;49:875-80

70. Yao SL, Lu-Yao G. Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stayJ NCI. 1999;91:1950-6

71. Alibhai SMH, Leach M, Tomlinson G. et al30-Day mortality and major complications after radical prostatectomy: influence of age and comorbidityJ NCI. 2005;97:1525-32

72. Potosky AL, Davis WW, Hoffman RM. et alFive-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes StudyJ NCI. 2004;96:1358-67

73. Lim AJ, Brandon AH, Fiedler J. et alQuality of life: radical prostatectomy versus radiation therapy for prostate cancerJ Urol. 1995;154:1420-5

74. Hamilton AS, Stanford JL, Gilliland FD. et alHealth outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes StudyJ Clin Oncol. 2001;19:2517-26

75. Fowler FJ Jr, McNaughton Collins M; Walker Corkery E. et alThe impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinomaCancer. 2002;95:287-95

76. Tsai HK, D'Amico AV, Sadetsky N. et alChen, MH; Carroll, PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortalityJNCI. 2007;99:1516-24

77. Punnen S, Nam RK. Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: A clinical conundrum in the PSA eraSurg Oncol. 2009;18:192-9

78. Cooner WH, Mosley BR, Rutherford CL Jr. et alProstate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigenJ Urol. 1990;143:1146-52

79. Brawer MK, Chetner MP, Beatie J. et alScreening for prostatic carcinoma with prostate carcinoma with prostate specific antigenJ Urol. 1992;147:841-5

80. Labrie F, Dupont A, Suburu R. et alSerum prostate specific antigen as pre-screening test for prostate cancerJ Urol.1992;147:846-51

81. Catalona WJ, Richie JP, Ahmann FR, et al.Comparison of digital rectal examination, serum prostate specific antigen in the early detection of prostate cancer. Results of a multicenter clinical trial of 6,630 menJ Urol. 1994;151:1283-90

82. Greenlee RT, Murray T, Bolden S. et alCancer statistics 2000CA Cancer J Clin. 2000;50:7-33

83. Potosky AL, Miller BA, Albertsen PC. et alThe role of increasing detection in the rising incidence of prostate cancer.JAMA. 1995;273:548-52

84. Moul JW. Treatment options for prostate cancer. Part I. Staged, grade, PSA, and changes in the 1990'sAm J Managed Care. 1998;4:1031-6

85. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality ratesEpidemiology. 2000;11:167-70

86. Smart CR. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results programCancer. 1997;80:1835-44

87. Mettlin CJ, Murphy GP, Rosenthal DS. et alThe National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society.Cancer. 1998;83:1679-84

88. Tarone RE, Chu KC, Brawley OW. Implications of stage specific survival rates in assessing recent declines in prostate cancer mortality ratesEpidemiology. 2000;11:167-70

89. Smart CR. The results of prostate carcinoma screening in the US as reflected in the Surveillance, Epidemiology, and End Results programCancer. 1997;80:1835-44

90. Mettlin CJ, Murphy GP, Rosenthal DS. et alThe National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the US. The American College of Surgeons Commission on Cancer and the American Cancer Society.Cancer. 1998;83:1679-84

91. Bunting PS. A guide to the interpretation of serum prostate specific antigen levelsClin Biochem. 1995;28:221-41

92. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer— part II: cause of death misclassification and the recent rise and fall in prostate cancer mortalityJ NCI. 1999;91:1025-32

93. Bettencourt MC, Bauer JJ, Sesterhenn IA. et alKi-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomyJ Urol. 1996;156:1064-8

94. Stephenson RA. Population-based prostate cancer trends in the PSA era: data from the Surveillance, Epidemiology, and End Results ProgramMonographs in Urology. 1998:3-19

95. Etzioni R, Legler JM, Feuer EJ. et alCancer surveillance series: interpreting trends in prostate cancer— part III: quantifying the link between population prostate specific antigen testing and recent declines in prostate cancer mortalityJ NCI. 1999;91:1033-9

96. Coley CM, Barry MJ, Fleming C. et alEarly detection of prostate cancer. Part 1. Prior probability and effectiveness of tests.Ann Intern Med. 1997;126(5):394-406

97. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markersClin Cancer Res. 2004;10:3943-53

98. Hartwell L, Mankoff D, Paulovich A. et alCancer biomarkers: a systems approachNature Biotechnology. 2006;24:905-8

99. Cox TM. Biomarkers in lysosomal storage diseases. Fabry disease: Perspectives from 5 years of FOSMehta, A; Beck, M; Sunder-Plassmann, G, editors. Oxford (UK): Oxford PharmaGenesis Ltd. 2006

100. A Framework for Biomarker and Surrogate Endpoint Use in Drug Development. Woodcock J.http://www.fda.gov/ohrms/dockets/ac/04/

101. Deegan PB, Moran MT, McFarlane I. et alClinical evaluation of chemokine and enzymatic biomarkers of Gaucher diseaseBlood Cells Mol Dis. 2005;35:259-67

102. Pepe MS, Etzioni R, Feng Z. et alPhases of biomarker development for early detection of cancerJ Natl Cancer Inst.2001;93:1054-61

103. Barker PE. Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST)Ann NY Acad Sci. 2003;983:142-50

104. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selectionNature Reviews Cancer.2005;5:845-56

105. Nadler RB, Humphrey PA, Smith DS. et alEffect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levelsJ Urol. 1995;154:407-13

106. Makarov DV, Loeb S, Getzenberg RH. et alBiomarkers for prostate cancerAnn Rev Medicine. 2009;60:139-51

107. Taskén KA, Angelsen A, Svindland A. et alMarkers for diagnosis, prediction and prognosis of prostate cancerTidsskr Nor Laegeforen. 2005;125:3279-82

108. Gutman AB, Gutman EB. An “acid” phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate glandJ Clin Invest. 1938;17:473-8

109. Veeramani S, Yuan TC, Chen SJ. et alCellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancerEndocr Relat Cancer. 2005;12:805-22

110. Gutman AB, Gutman EB, Robinson JN. Determination of serum 'acid' phosphatase activity in differentiating skeletal metastases secondary to prostatic carcinoma from Paget's disease of boneAm J Cancer. 1940;38:103-8

111. Doe RP, Seal US. Acid phosphatase in urologySurg Clin North Am. 1965;45:1455-66

112. Whitesel JA, Donohue RE, Mani JH. et alAcid phosphatase: its influence on the management of carcinoma of the prostateJ Urol. 1984;131:70-7

113. Johnson DE, Prout GR, Scott WW. et alClinical significance of serum acid phosphatase levels inadvanced prostatic carcinomaUrology. 1976;8:123-6

114. Bishop MC, Hardy JG, Taylor MC. et alBone imaging and serum phosphatases in prostatic carcinomaBr J Urol.1985;57:317-24

115. Lilja H, Haese A, Björk T. et alSignificance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomyJ Urol. 1999;162:2029-34

116. Sokoll LJ, Partin AW, Mikolajczyk SD. et alProPSA in relation to free PSA gives the best performance in detecting cancer in the 2.5-4.0 ng/mL total PSA rangeJ Urol. 2002;167:286

117. Ercole CJ, Lange PH, Mathisen M. et alProstatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancerJ Urol. 1987;138:1181-4

118. Pound CR, Partin AW, Eisenberger MA. et alNatural history of progression after PSA elevation following radical prostatectomyJAMA. 1999;281:1591-7

119. Lowe FC, Trauzzi SJ. Prostatic acid phosphatase in 1993. Its limited clinical utilityUrol Clin North Am. 1993;20:589-95

120. Han M, Piantadosi S, Zahurak ML. et alSerum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancerUrology. 2001;57:707-11

121. Oberaigner W, Horninger W. Klocker H. Schönitzer D; Stühlinger, W; Bartsch, G. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testingAm J Epidemiol. 2006;164:376-84

122. Antenor JA, Roehl KA, Eggener SE. et alPreoperative PSA and progression-free survival after radical prostatectomy for Stage T1c diseaseUrology. 2005;66:156-60

123. Nadler RB, Loeb S, Roehl KA. et alUse of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 yearsJ Urol. 2005;174:2154-7

124. Thompson IM, Pauler DK, Goodman PJ. et alPrevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliterN Engl J Med. 2004;350:2239-46

125. Han M, Partin AW, Chan DY. et alAn evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy seriesJ Urol. 2004;171:23-36

126. Han M, Partin AW, Pound CR. et alLong-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experienceUrol Clin North Am. 2001;28:555-65

127. Freedland SJ, Humphreys EB, Mangold LA. et alRisk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomyJAMA. 2005;294:433-9

128. Kuefer R, Varambally S, Zhou M. et alAlpha-methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiationAm J Pathol. 2002;161:841-8

129. Zha S, Ferdinandusse S, Denis S. et alAlpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancerCancer Res. 2003;63:7365-76

130. Jiang Z, Wu CL, Woda BA. et alAlpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer markerHistopathology. 2004;45:218-25

131. Rubin MA, Zhou M, Dhanasekaran SM. et alAlpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancerJAMA. 2002;287:1662-70

132. Jiang Z, Wu CL, Woda BA. et alP504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsyAm J Surg Pathol. 2002;26:1169-74

133. Luo J, Zha S, Gage WR. et alAlpha-methylacyl-CoA racemase: a new molecular marker for prostate cancerCancer Res.2002;62:2220-6

134. Rogers CG, Ya G, Zha S. et alProstate cancer detection on urinalysis for alpha methylacyl coenzyme A racemase proteinJ Urol. 2004;172:1501-3

135. Sreekumar A, Laxman B, Rhodes DR. et alHumoral immune response to alpha-methylacyl-CoA racemase and prostate cancerJ NCI. 2004;96:834-43

136. Cardillo MR, Gentile V, Ceccariello A. et alCan p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer?BMC Cancer. 2005;5:111

137. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistanceCrit Rev Biochem Mol Biol. 1995;30:445-600

138. Lee WH, Morton RA, Epstein JI. et alCytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesisProc Natl Acad Sci USA. 1994;91:11733-7

139. Harden SV, Guo Z, Epstein JI. et alQuantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinomaJ Urol. 2003;169:1138-42

140. Jerónimo C, Varzim G, Henrique R. et alI105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinomaCancer Epidemiol Biomarkers Prev. 2002;11:445-50

141. Jeronimo C, Usadel H, Henrique R. et alQuantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinomaJ NCI. 2001;93:1747-52

142. Chu DC, Chuang CK, Fu JB. et alThe use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinomaJ Urol. 2002;167:1854-8

143. Brooks JD, Weinstein M, Lin X. et alCG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasiaCancer Epidemiol Biomark Prev. 1998;7:531-6

144. Cairns P, Esteller M, Herman JG. et alMolecular detection of prostate cancer in urine by GSTP1 hypermethylationClin Cancer Res. 2001;7:2727-30

145. Lin X, Tascilar M, Lee WH. et alGSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cellsAm J Pathol. 2001;159:1815-26

146. Bastian PJ, Ellinger J, Schmidt D. et alGSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age?Eur J Med Res. 2004;9:523-7

147. Gonzalgo ML, Pavlovich CP, Lee SM. et alProstate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimensClin Cancer Res. 2003;9:2673-7

148. Gonzalgo ML, Nakayama M, Lee SM. et alDetection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysisUrology. 2004;63:414-8

149. Simon JP, Aunis D. Biochemistry of the chromogranin A protein familyBiochem J. 1989;262:1-13

150. Helman LJ, Ahn TG, Levine MA. et alMolecular cloning and primary structure of human chromogranin A (secretory protein I) cDNAJ Biol Chem. 1988;263:11559-63

151. Berruti A, Mosca A, Tucci M. et alIndependent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory diseaseEndocr Relat Cancer. 2005;12:109-17

152. Deftos LJ. Granin-A, parathyroid hormone-related protein, and calcitonin gene products in neuroendocrine prostate cancerProstate (Suppl). 1998;8:23-31

153. Berruti A, Dogliotti L, Mosca A. et alCirculating neuroendocrine markers in patients with prostate carcinomaCancer.2000;88:2590-7

154. Zaky Ahel M, Kovacic K, Kraljic I. et alOral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patientsAnticancer Res. 2001;21:1475-9

155. Ferrero-Pous M, Hersant AM, Pecking A. et alSerum chromogranin-A in advanced prostate cancerBJU Int. 2001;88:790-6

156. Cabrespine A, Guy L, Gachon F. et alCirculating chromogranin A and hormone refractory prostate cancer chemotherapy.J Urol. 2006;175:1347-52

157. Sasaki T, Komiya A, Suzuki H. et alChanges in chromogranin A serum levels during endocrine therapy in metastatic prostate cancer patientsEur Urol. 2005;48:224-30

158. Zitella A, Berruti A, Destefanis P. et alGruppo Oncologico Urologico Piemontese (GOUP). Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasiaClin Chim Acta. 2007;377:103-7

159. Ramírez ML, Nelson EC, Evans CP. Beyond prostate-specific antigen: alternate serum markersProstate Cancer Prostatic Diseases. 2008;11:216-29

160. Isshiki S, Akakura K, Komiya A. et alChromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancerJ Urol. 2002;167:512-5

161. Cheville JC, Tindall D, Boelter C. et alMetastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survivalCancer. 2002;95:1028-36

162. Fracalanza S, Prayer-Galetti T, Pinto F. et alPlasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free/total prostate-specific antigen determinationUrol Int. 2005;75:57-61

163. Deftos LJ, Abrahamsson PA. Granins and prostate cancerUrology. 1998;51:141-5

164. Riegman PH, Vlietstra RJ, Klaassen P. et alThe prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19FEBS Lett. 1989;247:123-6

165. Dawson NA, Vogelzang NJ. Prostate Cancer. New York: Wiley-Liss Inc. 1994

166. Myrtle JF, Klimley PG, Ivor LP. et alClinical utility of prostate specific antigen (PSA) in the management of prostate cancerAdvances in cancer diagnostics. San Diego, CA: Hybritech Inc. 1986:1-4

167. Xiao Z, Adam BL, Cazares LH. et alQuantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate diseaseCancer Res. 2001;61:6029-33

168. Wang TY, Kawaguchi TP. Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancerAnn Clin Lab Sci. 1986;16:461-6

169. Beckett ML, Cazares LH, Vlahou A. et alProstate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancerClin Cancer Res. 1999;5:4034-40

170. Murphy GP, Kenny GM, Ragde H. et alMeasurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancerUrology. 1998;51:89-97

171. Reiter RE, Gu Z, Watabe T. et alProstate stem cell antigen: a cell surface marker overexpressed in prostate cancerProc Natl Acad Sci USA. 1998;95:1735-40

172. Gu Z, Thomas G, Yamashiro J. et alProstate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancerOncogene. 2000;19:1288-96

173. Han KR, Seligson DB, Liu X. et alProstate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancerJ Urol. 2004;171:1117-21

174. Hara N, Kasahara T, Kawasaki T. et alReverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancerClin Cancer Res. 2002;8:1794-9

175. Ross S, Spencer SD, Holcomb I. et alProstate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugateCancer Res. 2002;62:2546-53

176. Saffran DC, Raitano AB, Hubert RS. et alAnti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenograftsProc Natl Acad Sci USA. 2001;98:2658-63

177. Dannull J, Diener PA, Prikler L. et alProstate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancerCancer Res. 2000;60:5522-8

178. Getzenberg RH, Pienta KJ, Huang EY. et alIdentification of nuclear matrix proteins in the cancer and normal rat prostate.Cancer Res. 1991;51:6514-20

179. Uetsuki H, Tsunemori H, Taoka R. et alExpression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostateJ Urol. 2005;174:514-8

180. Dhir R, Vietmeier B, Arlotti J. et alEarly identification of individuals with prostate cancer in negative biopsiesJ Urol.2004;171:1419-23

181. Hansel DE, DeMarzo AM, Platz EA. et alEarly prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsiesJ Urol. 2007;177:1736-40

182. Paul B, Dhir R, Landsittel D. et alDetection of prostate cancer with a blood-based assay for early prostate cancer antigenCancer Res. 2005;65:4097-100

183. Epstein JI, Pizov G, Steinberg GD. et alCorrelation of prostate cancer nuclear deoxyribonucleic acid, size, shape and Gleason grade with pathological stage at radical prostatectomyJ Urol. 1992;148:87-91

184. Partin AW, Steinberg GD, Pitcock RV. et alUse of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancerCancer. 1992;70:161-8

185. Babiarz J, Peters JM, Miles B. et alCrissman, JD. Comparison of DNA content in primary and lymph node metastases in prostate adenocarcinomaAnal Quant Cytol Histol. 1993;15:158-64

186. Veltri RW, Partin AW, Epstein JE. et alQuantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progressionJ Cell Biochem (Suppl). 1994;19:249-58

187. Carmichael MJ, Veltri RW, Partin AW. et alDeoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 diseaseJ Urol. 1995;153:1015-19

188. Badalament RA, Miller MC, Peller PA. et alRW. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen levelJ Urol. 1996;156:1375-80

189. Bubendorf L, Tapoa C, Gasser TC. et alKi67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancerHum Pathol. 1998;29:949-54

190. Su SL, Boynton AL, Holmes EH. et alDetection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reactionSemin Surg Oncol. 2000;18:17-28

191. Scherr DS, Vaughan EDJ, Wei J. et alBCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapyJ Urol. 1999;162:12-6

192. Feneley MR, Partin AW. Indicators of pathololgic stage of prostate cancer and their use in clinical practiceUrol Clin North Am. 2001;28:443-58

193. Kwiatkowski MK, Recker F, Piironen T. et alIn prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic “gray zone” of total PSA 4 to 10 ng/mlUrology. 1998;52:360-5

194. Becker C, Noldus J, Diamandis E. et alThe role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic diseaseCrit Rev Clin Lab Sci. 2001;38:357-99

195. Haese A, Becker C, Noldus J. et alHuman glandular kallikrein 2. A potential serum marker for predicting the organ-confined versus non-organ-confined growth of prostate cancerJ Urol. 2000;163:1491-7

196. Chapoval AI, Ni J, Lau JS. et alB7-H3: A costimulatory molecule for T cell activation and IFN-gamma productionNat Immunol. 2001;2:269-74

197. Suh WK, Gajewska BU, Okadal H. et alThe B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responsesNat Immunol. 2003;4:899-906

198. Zang X, Allison JP. The B7 family and cancer therapy: Costimulation and coinhibitionClin Cancer Res. 2007;13:5271-9

199. Luol L, Chapoval AI, Flies DB. et alB7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cellsJ Immunol. 2004;173:5445-50

200. Sun M, Richards S, Prasad DV. et alCharacterization of mouse and human B7-H3 genesJ Immunol. 2002;168:6294-7

201. Petroff MG, Kharatyan E, Torry DS. et alThe immunomodulatory proteins B7-DC, B7-H2, and B7-H3 are differentially expressed across gestation in the human placentaAm J Pathol. 2005;167:465-73

202. Hofmeyer KA, Ray A, Zang X. The contrasting role of B7-H3Proc Natl Acad Sci USA. 2008;105:10277-8

203. Roth TJ, Sheinin Y, Lohse CM. et alB7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapyCancer Res. 2007;67:7893-900

204. Zang X, Thompson RH, Al-Ahmadie HA. et alB7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcomeProc Natl Acad Sci USA. 2007;104:19458-63

205. Chavin G, Sheinin Y, Crispen PL. et alRJ. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastasesClin Cancer Res. 2009;15:2174-80

206. Tsai G, Lane HY, Yang P. et alGlycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophreniaBiol Psychiatry. 2004;55:452-6

207. Sreekumar A, Poisson LM, Rajendiran TM. et alMetabolomic profiles delineate potential role for sarcosine in prostate cancer progressionNature. 2009;457:799-800

208. Couzin J. Biomarkers. Metabolite in urine may point to high-risk prostate cancerScience. 2009;323:865

209. Razani B, Schlegel A, Lisanti MP. Caveolin proteins in signaling, oncogenic transformation and muscular dystrophyCell Sci. 2000;113:2103-9

210. Okamoto T, Schlegel A, Scherer PE. et alCaveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membraneJ Biol Chem. 1998;273:5419-22

211. Tirado OM, Maccarthy CM, Fatima N. et alCaveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing's sarcoma cells by modulating PKCalpha phosphorylationInt J Cancer. 2010;126(2):426-36

212. Liedtke C, Kersting C, Burger H. et alCaveolin-1 expression in benign and malignant lesions of the breastWorld J Surg Oncol. 2007;5:110

213. Shatz M, Liscovitch M. Caveolin-1: a tumor-promoting role in human cancerInt J Radiat Biol. 2008;84:177-89

214. Yang G, Addai J, Wheeler TM. et alCorrelative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesisHum Pathol. 2007;38:1688-95

215. Barresi V, Cerasoli S, Tuccari G. Correlative evidence that tumor cell-derived caveolin-1 mediates angiogenesis in meningiomasNeuropathology. 2008;28:472-8

216. Tahir SA, Yang G, Goltsov AA. et alTumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer.Cancer Res. 2008;68:731-9

217. Tahir SA, Yang G, Ebara S. et alSecreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancerCancer Res. 2001;61:3882-85

218. Yang G, Truong LD, Timme TL. et alElevated expression of caveolin is associated with prostate and breast cancerClin Cancer Res. 1998;4:1873-80

219. Yang G, Troung LD, Wheeler TM. et alCaveolin-1 expression in clinically confined human cancer: a novel prognostic markerCancer Res. 1999;59:5719-23

220. Thompson TC, Tahir SA, Li L. et alThe role of caveolin-1 in prostate cancer: clinical implicationsProstate Cancer Prostatic Dis. 2010;13:6-11

221. Di Vizio D, Morello M, Sotgia F. et alAn absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activationCell Cycle. 2009;8:2420-24

222. Tanase CP. Caveolin-1: a marker for pancreatic cancer diagnosisExpert Rev Mol Diagn. 2008;8:395-404

223. Lin KI, Chattopadhyay N, Bai M. et alElevated extracellular calcium can prevent apoptosis via the calcium-sensing receptorBiochem Biophys Res Commun. 1998;249:325-31

224. Vanaja DK, Grossmann ME, Cheville JC. et alPDLIM4, an actin binding protein, suppresses prostate cancer cell growth.Cancer Invest. 2009;27:264-72

225. Lallet-Daher H, Roudbaraki M, Bavencoffe A. et alIntermediate-conductance Ca2+=activated K+ channels (IKcal) regulate human prostate cancer cell proliferation through a close control of calcium entryOncogene. 2009;28:1792-806

226. Liao J, Schneider A, Datta NS. et alExtracellular calcium as a candidate mediator of prostate cancer skeletal metastasis.Cancer Res. 2006;77:9065-73

227. Schwartz GG. Is serum calcium a biomarker of fatal prostate cancer?Future Oncol. 2009;5:577-80

228. Vanaja DK, Ballman KV, Morlan BW. et alPDLIM4 repression by hypermethylation as a potential biomarker for prostate cancerClin Cancer Res. 2006;12:1128-36

229. Vanaja DK, Grossmann ME, Cheville JC. et alPDLIM4, an actin binding protein, suppresses prostate cancer cell growth.Cancer Invest. 2009;27:264-72

230. Bussemakers MJ, van Bokhoven A, Verhaegh GW. et alDD3: a new prostate-specific gene, highly overexpressed in prostate cancerCancer Res. 1999;59:5975-9

231. de Kok JB, Verhaegh GW, Roelofs RW. et alDD3 (PCA3), a very sensitive and specific marker to detect prostate tumors.Cancer Res. 2002;62:2695-98

232. Kirby RS, Fitzpatrick JM, Irani J. Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3)BJU Int. 2009Feb;103:441-5

233. Haese A, de la Taille A, van Poppel H. et alClinical utility of the PCA3 urine assay in European men scheduled for repeat biopsyEur Urol. 2008;54:1081-88

234. Marks LS, Fradet Y, Deras IL. et alPCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.Urology. 2007;69:532-5

235. Chun FK, de la Taille A, van Poppel H, et al.Prostate cancer gene 3 (PCA3). development and internal validation of a novel biopsy nomogramEur Urol. 2009;56:659-68

236. Nakanishi H, Groskopf J, Fritsche HA. et alPCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillanceJ Urol. 2008;179:1804-9

237. Whitman EJ, Groskopf J, Ali A. et alPCA3 score before radical prostatectomy predicts extracapsular extension and tumor volumeJ Urol. 2008;180:1975-8

238. Wang R, Chinnaiyan AM, Dunn RL. et alRational approach to implementation of prostate cancer antigen 3 into clinical careCancer. 2009;115:3879-86

239. Phé V, Rouprêt M, Salomon L. et alWhat's new in 2008 in the field of basic and clinical research in prostate cancer?.Prog Urol. 2009;19:S29-42

240. Fradet Y, Saad F, Aprikian A. et aluPM3, a new molecular urine test for the detection of prostate cancerUrology.2004;64:311-5

241. Hessels D, Klein Gunnewiek JM, van Oort I. et alDD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancerEur Urol. 2003;44:8-15

242. Groskopf J, Aubin SM, Deras IL. et alAPTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancerClin Chem. 2006;52:1089-95

243. Deras IL, Aubin SM, Blasé A. et alPCA3: a molecular urine assay for predicting prostate biopsy outcomeJ Urol.2008;179:1587-92

244. Ankerst DP, Groskopf J, Day JR. et alPredicting prostate cancer risk through incorporation of prostate cancer gene 3J Urol. 2008;180:1303-8

245. Marks LS, Bostwick DG. Prostate cancer specificity of PCA3 gene testing: examples from clinical practiceRev Urol.2008;10:175-81

246. Shappell SB, Fulmer J, Arguello D. et alPCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory settingUrology. 2009;73:363-8

247. Ouyang B, Bracken B, Burke B. et alA duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancerJ Urol. 2009;181:2508-13

248. Clarke RA, Zhao Z, Guo AY. et alNew genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progressionPLoS One. 2009;4:e4995

249. Wilson S, Greer B, Hooper J. et alThe membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cellsBiochem J. 2005;388:967-72

250. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancerNat Rev Cancer. 2008;8:497-511

251. Tomlins SA, Rhodes DR, Perner S. et alRecurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancerScience. 2005;310:644-8

252. Mwamukonda K, Chen Y, Ravindranath L. et alQuantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion statusProstate Cancer Prostatic Dis. 2010;13:47-5

253. Cai C, Wang H, Xu Y. et alReactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancerCancer Res. 2009;69:6027-32

254. Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognosis of prostate cancerClin Chem.2008;54:1951-60

255. Gerdes J, Schwab U, Lemke H. et alProduction of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferationInt J Cancer. 1983;31:13-20

256. Mosquera JM, Mehra R, Regan MM. et alPrevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United StatesClin Cancer Res. 2009;15:4706-11

257. Yoshimoto M, Joshua AM, Cunha IW. et alAbsence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcomeMod Pathol. 2008;21:1451-60

258. Fradet Y. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigenCurr Opin Urol.2009;19:243-6

259. Keller S, Sanderson MP, Stoeck A. et alExosomes: from biogenesis and secretion to biological functionImmunol Lett.2006;107:102-8

260. Valadi H, Ekström K, Bossios A. et alExosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cellsNat Cell Biol. 2007;9:654-9

261. Nilsson J, Skog J, Nordstrand A. et alProstate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancerBr J Cancer. 2009;100:1603-7

262. Mitchell PJ, Welton J, Staffurth J, Court J. et alCan urinary exosomes act as treatment response markers in prostate cancer?J Transl Med. 2009Jan12;7:4

263. Jansen FH, Krijgsveld J, van Rijswijk A. et alExosomal secretion of cytoplasmic prostate cancer xenograft-derived proteinsMol Cell Proteomics. 2009;8:1192-205

264. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknownJ Cell Physiol. 2000;182:311-22

265. Gerdes J, Lemke H, Baisch H. et alCell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67J Immunol. 1984;133:1710-5

266. Khatami A, Hugosson J, Wang W. et alKi-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.Scand J Urol Nephrol. 2009;43:12-8

267. Berney DM, Gopalan A, Kudahetti S. et alKi-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group studyBr J Cancer. 2009;100:888-93

268. Khor LY, Bae K, Paulus R. et alMDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02J Clin Oncol. 2009;27:3177-84

269. Jhavar S, Bartlett J, Kovacs G. et alBiopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillanceProstate Cancer Prostatic Dis. 2009;12:143-7

270. Wright LM, Yong S, Picken MM. et alDecreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2)Int J Clin Exp Pathol. 2009;2:34-47

271. Wei S, Dunn TA, Isaacs WB. et alGOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus.Prostate. 2008;68:1387-95

272. Laxman B, Morris DS, Yu J. et alA first-generation multiplex biomarker analysis of urine for the early detection of prostate cancerCancer Res. 2008;68:645-9

273. Kristiansen G, Fritzsche FR, Wassermann K. et alGOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnosticsBr J Cancer. 2008;99:939-48

274. Chen H, Pong RC, Wang Z. et alDifferential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterizationGenomics. 2002;79:573-81

275. Chen H, Toyooka S, Gazdar AF. et alEpigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell linesJ Biol Chem. 2003;278:3121-30

276. Wang Z, Tseng CP, Pong RC. et alThe mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2J Biol Chem.2002;277:12622-31

277. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancerJ Biol Chem. 2005;280:22437-44

278. Chen H, Toyooka S, Gazdar AF. et alEpigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell linesJ Biol Chem. 2003;278:3121-30

279. Duggan D, Zheng SL, Knowlton M. et alTwo genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IPJ Natl Cancer Inst. 2007;99:1836-44

Информация для заказа

Наименование ОбъемПроизводствоМетод Кат.Номер
ИФА набор Human Antigen KI-67 (Ki-67) ELISA Kit  96Cusabio ELISA CSB-E16294h 
ИФА набор Human Apolipoprotein A2,apo-A2 ELISA Kit  96Cusabio ELISA CSB-E13504h 
ИФА набор Human calcitonin gene related peptide,CGRP ELISA Kit  96Cusabio ELISA CSB-E08210h 
Ифа набор Human Catenin beta-1 (CTNNB1/CTNNB/OK/SW-cl.35/PRO2286) ELISA kit  96Cusabio ELISA CSB-E08963h 
ИФА набор Human Caveolin-1,Cav-1 ELISA KIT  96Cusabio ELISA CSB-E09682h 
ИФА набор Human Chromogranin,CgA ELISA Kit  96Cusabio ELISA CSB-E09153h 
ИФА набор Human Disabled homolog 2-interacting protein(DAB2IP) ELISA kit  96Cusabio ELISA CSB-EL006481HU 
ИФА набор Human E-Cadherin,E-Cad ELISA Kit  96Cusabio ELISA CSB-E04519h 
ИФА набор Human epidermal growth factor receptor 2 (sp185/HER2) ELISA Kit  96Cusabio ELISA CSB-E11161h 
Ифа набор Human epidermal growth factor receptor,EGFR ELISA Kit  96Cusabio ELISA CSB-E12124h 
ИФА набор Human Free Prostate Specific Antigen,fPSA ELISA Kit  96Cusabio ELISA CSB-E04769h 
ИФА набор Human Free Testosterone,F-TESTO ELISA Kit  96Cusabio ELISA CSB-E05096h 
ИФА набор Human Glutamate carboxypeptidase 2(FOLH1) ELISA kit  96Cusabio ELISA CSB-EL008782HU 
ИФА набор Human hepatocyte growth factor,HGF ELISA kit  96Cusabio ELISA CSB-E04573h 
ИФА набор Human High Sensitive Interleukin 6(IL-6) ELISA Kit  96Cusabio ELISA CSB-E16546h 
ИФА набор Human Interleukin 6,IL-6 ELISA KIT  96Cusabio ELISA CSB-E04638h 
ИФА набор Human Kallikrein 2(hK 2) ELISA Kit  96Cusabio ELISA CSB-E13094h 
ИФА набор Human Leptin,LEP ELISA kit  96Cusabio ELISA CSB-E04649h 
ИФА набор Human Macrophage Migration Inhibitory Factor,MIF ELISA Kit  96Cusabio ELISA CSB-E08330h 
ИФА набор Human matrix metalloproteinase 9/Gelatinase B,MMP-9 ELISA Kit  96Cusabio ELISA CSB-E08006h 
ИФА набор Human Neuron-specific enolase,NSE ELISA Kit  96Cusabio ELISA CSB-E07961h 
ИФА набор Human pro-gastrin-releasing peptide, ProGRP ELISA Kit  96Cusabio ELISA CSB-E09127h 
ИФА набор Human prostate specific antigen,PSA ELISA Kit  96Cusabio ELISA CSB-E04768h 
ИФА набор Human Prostate stem cell antigen(PSCA) ELISA kit  96Cusabio ELISA CSB-EL018840HU 
ИФА набор Human sex hormone-binding globulin,SHBG ELISA Kit  96Cusabio ELISA CSB-E08232h 
ИФА набор Human Soluble Endoglin,sENG/sCD105 ELISA Kit  96Cusabio ELISA CSB-E10030h 
ИФА набор Human thrombospondin 1,TSP-1 ELISA Kit  96Cusabio ELISA CSB-E08763h 
ИФА набор Human Tissue Inhibitor Of Matrix Metalloprotease-1 (TIMP-1) ELISA KIT  96Cusabio ELISA CSB-E08003h 
ИФА набор Human tissue inhibitors of metalloproteinase 2,TIMP-2 ELISA Kit  96Cusabio ELISA CSB-E04733h 
ИФА набор Human total prostate s pecific antigen,tPSA ELISA Kit  96Cusabio ELISA CSB-E09627h 
ИФА набор Human Transforming Growth factor β1,TGF-β1 ELISA kit  96Cusabio ELISA CSB-EL023446HU 
ИФА набор Human transforming growth factor α,TGF-α ELISA Kit  96Cusabio ELISA CSB-E04724h 
ИФА набор Human Transforming Growth factor β3,TGF-β3 ELISA kit  96Cusabio ELISA CSB-E13738h 
ИФА набор Human transforming growth factors β2,TGFβ2 ELISA Kit  96Cusabio ELISA CSB-E09783h 
ИФА набор Human Ultra Sensitive Prostate Specific Antigen,PSA U S ELISA Kit  96Cusabio ELISA CSB-E08989h 
ИФА набор Human Urokinase-type Plasminogen Activator Receptor,PLAUR/uPAR ELISA kit  96Cusabio ELISA CSB-E04752h 
ИФА набор Human Vascular Endothelial cell Growth Factor(VEGF) ELISA KIT  96Cusabio ELISA CSB-E-11718h 
Хромогранин А  96 wellsDako ELISA K002511 
   
© ООО «Лабораторная Диагностика»,  info@LD.ru
телефоны: +7 (495) 461-67-60, +7 (499) 348-25-72